We talk about dry eye disease (DED) constantly, and for good reason. Depending on the study, it affects somewhere between 5% and 50% of the global population, runs up roughly $3.8 billion a year in US healthcare costs, and accounts for a huge share of the chief complaints we hear in clinic every single day.1,2
We have more tools than ever: artificial tears, anti-inflammatory drops, immunomodulators, neuromodulators, tear film stabilizers, and in-office procedures. Still, a lot of patients, particularly those on the moderate-to-severe end, continue to struggle.3
Enter TFOS DEWS III. The 2025 report updated the definition of dry eye, refined how we diagnose it, and introduced a prescribing algorithm that finally puts the emphasis where it belongs: on treating the root cause, not just chasing symptoms.4,5 For a practical breakdown, check out: What Optometrists Need to Know About TFOS DEWS III with Cheat Sheet.
A handful of emerging therapies (gene editing, stem cells, gut health, biologics, nanotechnology) are starting to push dry eye care past symptom management and toward something closer to actual disease modification.
Gene therapy and precision medicine
Nobody is using gene therapy for DED in-clinic yet, but the preclinical work is worth paying attention to. Animal studies have shown that nanoparticle carriers can deliver a gene that ramps up mucin 5AC (MUC5AC), one of the mucins that tends to be depleted in DED, leading to better tear production and less surface inflammation.6
CRISPR, the gene-editing tool that has dominated headlines in other areas of medicine, has already reached human trials for inherited retinal diseases and glaucoma.7,8 Those trials are laying the groundwork (safety data, regulatory pathways) that could eventually open the door for dry eye applications targeting the lacrimal and meibomian glands.8
The nearer-term opportunity is probably precision medicine. Genetic studies have pinpointed risk factors for autoimmune-driven dry eye, and researchers are identifying tear-based biomarkers (proteins, lipid profiles, small RNA molecules) that could let us subtype patients with much more specificity and tailor treatment accordingly.5,9,10
Stem cell and regenerative therapies
Stem cell therapies do not just mask symptoms. They go after inflammation, tissue damage, and immune dysfunction at the source.11
Most approaches use mesenchymal stem cells (MSCs), which release anti-inflammatory and tissue-repair signals that calm overactive immune pathways and promote regeneration of damaged lacrimal gland and ocular surface tissue.11,12 In clinical studies so far, delivery has taken two main forms: direct injection of MSCs into the lacrimal gland, and topical MSC-derived eye drops applied to the ocular surface.13,14
A 2026 review that pooled six clinical studies (131 patients total) found stem cell treatments delivered real, measurable gains:15
- Tear production went up (Schirmer scores increased by nearly 5mm)
- Tear film stability improved (tear breakup time [TBUT] improved significantly)
- The ocular surface looked healthier (corneal staining scores dropped)
- Patients felt better (OSDI scores improved by over 11 points).
Moreover, no serious adverse events were reported, though follow-up was limited.15
One pilot trial took things a step further: eye drops derived from umbilical cord stem cells were given twice daily for 2 weeks to patients with refractory dry eye, both Sjögren's and non-Sjögren's. The drops reduced inflammatory markers (IL-6, IL-17A) in the tears and led to improvements in tear production, meibomian gland function, and mucin levels.14
In a separate randomized trial, a single injection of adipose-derived MSCs into the lacrimal gland of Sjögren's patients improved TBUT and ocular surface staining over 12 months of follow-up.13
There is also growing interest in exosomes, tiny particles that stem cells release naturally. They carry many of the same repair signals as whole cells but are easier to manufacture and store, and less likely to cause an immune reaction.11,16 Down the road, these approaches could mean actually restoring damaged lacrimal glands, meibomian glands, and corneal nerves in patients with severe evaporative or neurotrophic disease.17
The gut microbiome–ocular surface connection
Gut health and dry eye. It sounds like a stretch, but the science is catching up to the idea. Patients with DED, especially autoimmune subtypes like Sjögren's, consistently show different gut bacteria profiles than healthy controls.18,19
The working theory: When gut bacteria fall out of balance, systemic inflammation ramps up, and some of that inflammation reaches the lacrimal glands and ocular surface via the bloodstream.20 One animal study drove the point home by transplanting gut bacteria from dry eye mice into healthy mice, which actually produced dry eye signs in the recipients.20
Probiotics are the obvious therapeutic angle, and early results are encouraging:
- A randomized trial showed that 4 months of oral probiotic and prebiotic supplements improved dry eye symptoms compared to placebo and helped stabilize the tear film.21
- A probiotic blend called IRT5 improved tear production and reduced ocular surface staining in autoimmune dry eye mouse models by calming overactive immune responses.22
- Specific strains of Lactobacillus and Bifidobacterium boosted tear output and reduced inflammation by rebalancing gut bacteria in animal models.23
This is not ready for a standard treatment protocol, but for patients with systemic inflammatory conditions, dietary changes and gut-focused therapies may eventually become a meaningful piece of the management puzzle.19
Biologics and blood-derived therapies
Autologous serum tears have been around for years, but the biologic toolkit is expanding fast. TFOS DEWS III now formally includes autologous serum and platelet-rich plasma (PRP) as recognized treatment options.4
A 2024 network meta-analysis compared 16 randomized trials (898 patients) across six different blood-based products. The highlights:24
- PRP drops came out on top for reducing corneal staining and improving symptom scores.
- Umbilical cord serum was best for boosting tear production and tear film stability.
- Every blood-derived product outperformed artificial tears.
Topical immunoglobulin therapy has shown promise in severe inflammatory dry eye, including graft-versus-host disease.25 TNF-alpha blockers and other targeted immune therapies are being studied for the most refractory cases.26
What makes biologics compelling is what they contain: growth factors, anti-inflammatory molecules, and tissue-repair signals that no synthetic drop has been able to replicate. They occupy a unique space between conventional pharmaceuticals and regenerative medicine.25,27
Nanoimplants and sustained drug delivery
Compliance remains one of the hardest problems in chronic dry eye care. Conventional drops typically deliver less than 5% of their medication to the target tissue.28,29 The rest is lost to tear drainage, blinking, and nasolacrimal absorption. Multiply that by three or four instillations a day, and it is easy to see why so many patients fall off their regimen.
Nanotechnology is tackling this from several angles:
- Nanoparticle formulations that help drugs penetrate better and stay on the ocular surface longer. A cyclosporine nanoemulsion is already FDA-approved.30
- Temperature-responsive gels that go on as a liquid drop and convert to a sustained-release gel once they reach the warm surface of the eye.28,31
- Drug-eluting canalicular inserts that sit in the tear drainage system and release medication steadily over weeks. A randomized trial of a dexamethasone insert showed significantly less corneal and conjunctival staining at 4 weeks versus sham.32
- Gel-based canalicular occlusion that combines tear conservation with sustained symptom and sign improvement through 6 months.33
The appeal is straightforward: fewer drops, steadier drug levels, less preservative exposure, and better long-term disease control.30
Key takeaways
- Gene therapy for dry eye is preclinical but progressing. Nanoparticle-delivered gene treatments and CRISPR editing are being explored to restore mucin production, reduce inflammation, and improve gland function.
- Stem cell therapies have reached early human trials with meaningful improvements in tear production, surface health, and symptoms, and no serious adverse events so far.
- The concept of the gut-eye axis is gaining support. Gut bacteria imbalances are tied to ocular surface inflammation, and early evidence supports probiotics as a potential add-on therapy.
- Biologics go well beyond autologous serum. PRP, umbilical cord serum, immunoglobulin therapy, and targeted immune treatments are expanding options for even refractory patients.
- Sustained-release nanotechnology could change the compliance equation. Drug-releasing implants, smart gels, and nanocarrier systems aim to deliver consistent treatment with fewer daily drops.
Looking ahead
Not all of these therapies will make it from the lab to the exam lane. However, the trend is clear, and for our toughest cases, the options ahead look genuinely promising.
